DEVELOPING — SINGLE SOURCE, NOT YET CORROBORATED
China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
🚨 INNOCARE PHARMA SIGNS STRATEGIC DEAL WITH ELI LILLY Beijing-based InnoCare Pharma said on Thursday it entered a strategic research collaboration and licensing agreement with Eli Lilly. The deal could be worth up to US$3.35 billion. Source: South China Morning Post #China